Stochastic modelling Clause Samples

Stochastic modelling. ‌ There are relatively few tool-supported approaches for supporting the anal- ysis of stochastic models, and only limited experience in applying these to industry-scale problems. In WP2, Siemens has identified this as a priority in order to provide an analytic framework for discussing system-level failure rates on varying assumptions about specific component or infrastructure reli- abilities. Neither the Event-B language nor the Rodin tools currently support specification or analysis of probabilistic systems. Our initial work has focused on exploring the options for incorporating stochastic behaviour into Event-B models (Chapter 21). A case study inspired by the Siemens WP2 mini-pilot, on the behaviour of an emergency brake system in the presence of faults, has been a valuable focus point and forms the basis of a further study [And09] to be published shortly after the reporting period of this deliverable. This will compare Continuous Time Markov Chain approaches with proof-based techniques and lead to proposals for extensions to Event-B addressing this area. Part II‌ Chapter 5‌ This chapter provides an overview of existing requirements engineering methods. Prior to any formal modelling, it is important to structure infor- mal requirements to ensure that the formal model realises what had been requested. Informal requirements documents typically present requirements in terms of disparate levels of abstraction and traceability to an Event-B model is rarely straightforward. We expect a suitable requirements engineering method to support trace- ability through the different abstraction levels of a refinement-based formal development. It should enable systematic validation of requirements through- out the development cycle. 5.1 provides an overview of current research that directly concerns the issues Deploy attempts to solve; Section 5.2 elaborates on the methods that have been used so far; Section 5.3 briefly lists the methods that we are aware of but haven’t considered pursuing at this point; we close with Section 5.4, where we outline our plans for the future.
View Source

Related to Stochastic modelling

  • WILD AND SCENIC RIVERS The Wild and Scenic Rivers Act of 1968 (16 U.S.C. § 1271, et seq.) as amended, particularly sections 7(b) and (c) (16 U.S.C. § 1278(b) and (c)). AIR QUALITY The Clean Air Act (42 U.S.C. § 7401, et seq.) as amended, particularly sections 176(c) and (d) (42 U.S.C. §7506(c) and (d)). Determining Conformity of Federal Actions to State or Federal Implementation Plans (Environmental Protection Agency-40 C.F.R. Parts 6, 51, and 93).

  • Infrastructure Vulnerability Scanning Supplier will scan its internal environments (e.g., servers, network devices, etc.) related to Deliverables monthly and external environments related to Deliverables weekly. Supplier will have a defined process to address any findings but will ensure that any high-risk vulnerabilities are addressed within 30 days.

  • VOETSTOOTS The PROPERTY is sold: 8.1. Voetstoots in accordance with the Sectional Plan and the participation quota endorsed thereon with the opening of the Sectional Title Register, or as they are endorsed already, and any amendments or adjustments thereto from time to time in accordance with the terms of the Act and without any warranties express or implied, the SELLER shall not be liable for any patent or latent defects. Should the extent of the Section or of the PROPERTY differ from that which is contained in the title deed or sectional plan or any amendment thereto, the SELLER shall not be liable for any shortfall or be entitled to any compensation for any surplus. 8.2. Subject to all the conditions and Regulations of the Act. 8.3. The PURCHASER acknowledges that this is not a construction contract and that he is purchasing a completed unit. The PURCHASER shall not have the right to interfere in any way with the building operations of the SELLER’S employees. He shall also have no right to retention. This Clause is also applicable in the case of the bank holding back any retention amount out of its own accord or on request of the PURCHASER. 8.4. The SELLER undertakes to erect the unit according to the general building standards as set by Financial Institutions. The unit is be registered with the NHBRC. 8.5. Should a dispute arise or be declared, such dispute shall be resolved by an Arbitrator appointed by the Developer. The costs in respect thereof shall be borne by the unsuccessful party. Pending the outcome of the dispute, the PURCHASER shall be obliged to pay the outstanding amount to the Conveyancers who shall hold it in trust.

  • Value Engineering The Supplier may prepare, at its own cost, a value engineering proposal at any time during the performance of the contract. The value engineering proposal shall, at a minimum, include the following; a) the proposed change(s), and a description of the difference to the existing contract requirements; b) a full cost/benefit analysis of the proposed change(s) including a description and estimate of costs (including life cycle costs) the Procuring Entity may incur in implementing the value engineering proposal; and c) a description of any effect(s) of the change on performance/functionality.

  • Platby In consideration for the proper performance of the Study by Institutionin compliance with the terms and conditions of this Agreement, payments shall be made in accordance with the provisions set forth in Attachment A, with the last payment being made after the Site completes all its obligations hereunder, and IQVIA has received all properly completed CRFs and, if IQVIA requests, all other Confidential Information (as defined below. DrugDev will receive Site invoices and process payments unless otherwise agreed. Any queries regarding Institution invoices or payments should be directed to ▇▇▇▇▇▇▇ at the contact details outlined in Attachment A. V souvislosti s řádným plněním Studie Poskytovatelem, a to v souladu s podmínkami a ustanoveními této Smlouvy, budou poskytovány platby dle podmínek a ustanovení definovaných v Příloze A, přičemž poslední platba bude uskutečněna poté, co Místo provádění klinického hodnocení splní a dokončí veškeré závazky, jež mu vyplývají z této Smlouvy, a IQVIA obdrží veškeré řádně vyplněné CRF a, bude-li tak IQVIA vyžadovat, veškeré další Důvěrné informace (ve smyslu níže uvedené definice). Nebude-li ujednáno jinak, faktury bude Místo provádění klinického hodnocení zasílat společnosti DrugDev, která je bude proplácet. Veškeré dotazy ohledně faktur Místa provádění klinického hodnocení nebo plateb je třeba směřovat na společnost DrugDev, jejíž kontaktní údaje jsou uvedeny v Příloze A.